文献类型：期刊文献

英文题名：Combined use of low T3 syndrome and NT-proBNP as predictors for death in patients with acute decompensated heart failure

作者：Zhao, Xinke[1];Zhang, Rongcheng[1];Jiang, Hugang[2];Liu, Kai[2];Ma, Chengxu[2];Bai, Ming[3];An, Tao[1];Yao, Younan[1];Wang, Xinqiang[2];Wang, Ming[2];Li, Yingdong[2];Zhang, Yuhui[1];Zhang, Jian[1]

第一作者：Zhao, Xinke

通信作者：Zhang, YH[1];Zhang, J[1];Li, YD[2]

机构：[1]Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Heart Failure Ctr, Natl Ctr Cardiovasc Dis, 167 Beilishi Rd, Beijing 100037, Peoples R China;[2]Gansu Univ Chinese Med, Affiliated Hosp, Dept Cardiol, 732 Jiyuguanxi Rd, Lanzhou 730000, Peoples R China;[3]Lanzhou Univ, Hosp 1, Dept Cardiol, Lanzhou 730000, Peoples R China

第一机构：Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Heart Failure Ctr, Natl Ctr Cardiovasc Dis, 167 Beilishi Rd, Beijing 100037, Peoples R China

通信机构：[1]corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Heart Failure Ctr, Natl Ctr Cardiovasc Dis, 167 Beilishi Rd, Beijing 100037, Peoples R China;[2]corresponding author), Gansu Univ Chinese Med, Affiliated Hosp, Dept Cardiol, 732 Jiyuguanxi Rd, Lanzhou 730000, Peoples R China.|[10735b845793de6ae2b30]甘肃中医药大学第二附属医院;[10735]甘肃中医药大学;

年份：2021

卷号：21

期号：1

外文期刊名：BMC ENDOCRINE DISORDERS

收录：;Scopus(收录号：2-s2.0-85108992860);WOS:【SCI-EXPANDED(收录号:WOS:000669203900001)】；

基金：This study was supported by grants from Scientific research project of preventing and treating major diseases of TCM (No. GZKZD-2018-02), Gansu province, China. Evidence-based capacity building project of Chinese medicine(2019XZZX-XXG002),Science and Technology Department of State Administration of Traditional Chinese Medicine, China. and National key R&D plan (No. 2017YFC1308300), Mister of Science and Technology of the people's Republic of China, China.

语种：英文

外文关键词：Acute decompensated heart failure; Low T3 syndrome; NT-proBNP; Mortality

摘要：Background In patients with established HF, low triiodothyronine syndrome (LT3S) is commonly present, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a useful marker for predicting death. This study was aimed to evaluate the prognostic value of LT3S in combination with NT-proBNP for risk of death in patients with heart failure (HF). Methods A total of 594 euthyroid patients hospitalized with acute decompensated HF were enrolled by design. Of these patients, 27 patients died during hospitalization and 100 deaths were identified in patients discharged alive during one year follow-up. Patients were divided into 2 groups on the base of the reference ranges of free T3 (FT3) levels: LT3S group (FT3 < 2.3pg/mL, n = 168) and non-LT3S group (FT3 >= 2.3pg/mL, n = 426). Results In multivariable Cox regression, LT3S was significantly associated with 1 year all-cause mortality (adjusted hazard ratio, 1.85; 95 % confidence interval [CI], 1.21 to 2.82; P = 0.005), but not significant for in-hospital mortality (adjusted hazard ratio, 1.58; 95 % CI, 1.58 to 2.82; P = 0.290) after adjustment for clinical variables and NT-proBNP. Addition of LT3S and NT-proBNP to the prediction model with clinical variables significantly improved the C statistic for predicting 1 year all-cause mortality. Conclusions In patients with acute decompensated HF, the combination of LT3S and NT-proBNP improved prediction for 1 year all-cause mortality beyond established risk factors, but was not strong enough for in-hospital mortality.